VIVS

8-K - VivoSim Labs, INC. (0001497253) (Filer)

DEF 14A - VivoSim Labs, INC. (0001497253) (Filer)

PRER14A - VivoSim Labs, INC. (0001497253) (Filer)

10-Q - VivoSim Labs, INC. (0001497253) (Filer)

EFFECT - VivoSim Labs, INC. (0001497253) (Filer)

PRE 14A - VivoSim Labs, INC. (0001497253) (Filer)

8-K - VivoSim Labs, INC. (0001497253) (Filer)

SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that on August 4, 2026, we received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1) which requires registrants to maintain a minimum stockholders’ equity of $2.5M. Subsequent to the filing of its recent Annual Report on Form 10-K for the fiscal year ended March 31, 2026, filed with the SEC on July 14, 2026 (the "Form 10-K"), the Company receiv

S-1 - VivoSim Labs, INC. (0001497253) (Filer)

8-K - VivoSim Labs, INC. (0001497253) (Filer)

8-K - VivoSim Labs, INC. (0001497253) (Filer)

SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced its first commercial sales in China, opening a significant new market for its NAMkind™ testing services. VivoSim delivers both toxicology and efficacy testing built on its 3D human tissue models of the liver and gastrointestinal (GI) tract. The two initial engagements, with a leading Shanghai-based oncology biotech and a large Chengdu-based pharmaceutical company, represent the Company’s first paid programs on the Chinese mainland and a milestone in VivoSim’s expansion across Asia-

8-K - VivoSim Labs, INC. (0001497253) (Filer)

SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the purchase and sale of 4,705,883 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,705,883 shares of common stock at an effective combined price of $0.85 per share and accompanying common warrant for aggregate gross proceeds of approximately $4.0 million, before deducting placement agent fe

DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Today’s announcements from NeOnc Technologies (NASDAQ:NTHI), Ernexa Therapeutics (NASDAQ:ERNA), and VivoSim Labs (NASDAQ:VIVS) highlight three distinct pathways to potential value creation. NeOnc Technologies NeOnc Technologies (NASDAQ:NTHI) announced that it has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing, and controls (CMC) development program for its lead drug candidate, NEO212, a novel temozolomide-perillyl alcohol conjugate being developed for malignant brain tumors and other central nervous system cancers. Rather than proceeding with its scheduled Type B

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue guidance for FY2027, and announced that it has received a $5 million payment from Eli Lilly. In association with its former inflammatory bowel disease drug program developed previously and sold outright to Eli Lilly, VivoSim has received $5 million as a milestone payment. The payment represents the dosing of the first patient in Phase 2 studies of the drug in Eli Lilly’s development program. The drug’s development is entirely guided by Eli Lilly,

10-K - VivoSim Labs, INC. (0001497253) (Filer)

NT 10-K - VivoSim Labs, INC. (0001497253) (Filer)

SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the availability of an AI prediction tool leveraging its NAMkind™ intestinal models to accurately predict the potential of a given drug compound to cause diarrhea in patients. The tool integrates its proprietary NAMkind™ ileum and colon tissues with advanced machine‑learning analytics to identify drug‑induced disruptions to intestinal epithelial integrity and function. Tissue-based assay data is used to train an AI predictive model in a process VivoSim has named VitroSense™. The

8-K - VivoSim Labs, INC. (0001497253) (Filer)

424B4 - VivoSim Labs, INC. (0001497253) (Filer)

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS), (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the pricing of up to a $4 million best-efforts public offering, with $3 million funded at an initial closing of the offering (the "Initial Closing") and another $1 million to be funded on the 30th day following the date of the Initial Closing, subject to the satisfaction of certain conditions (the "Second Closing"). The Initial Closing of the offering is expected to occur on, April 1, 2026, subject to the satisfaction of customary closing conditions. The Initial Closing of the p

EFFECT - VivoSim Labs, INC. (0001497253) (Filer)

S-1/A - VivoSim Labs, INC. (0001497253) (Filer)

S-1 - VivoSim Labs, INC. (0001497253) (Filer)